The Oncology Institute, Inc.
4.7000+0.02 (+0.43%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · TOI · USD
Key Stats
Market Cap
439.47MP/E (TTM)
-Basic EPS (TTM)
-0.67Dividend Yield
0%Recent Filings
8-K
TOI Q2 revenue surges 21.5%
The Oncology Institute reported Q2 2025 revenue of $119.8 million, up 21.5% from $98.6 million last year, fueled by 40% pharmacy growth to $62.6 million and 50,000 new capitated lives. Gross profit rose 34.4% to $17.5 million, while net loss widened slightly to $17.0 million; Adjusted EBITDA improved to $(4.1) million from $(8.7) million. Momentum from Florida expansion and Nevada Medicaid deal positions TOI for high-end 2025 revenue guidance of $460-480 million. Losses persist amid capitation risks.
8-K
Board Chair retires; McGeorge steps up
The Oncology Institute announced Richard Barasch's retirement from the Board of Directors and Chair role, effective August 12, 2025, with no disagreements cited. Anne McGeorge, current Board member and Audit Committee Chair with over 35 years in healthcare finance—including building Grant Thornton's $250 million global practice—succeeds him. Her expertise bolsters strategic guidance amid TOI's value-based oncology expansion. Smooth transition ahead.
10-Q
Q2 FY2025 results
The Oncology Institute posted Q2 revenue of $119.8M, up 21.5% y/y from $98.6M, driven by dispensary growth of 40.8% y/y to $62.6M while patient services rose 6.5% y/y to $55.9M; clinical trials revenue fell 20.2% y/y to $1.3M after outsourcing. Operating loss narrowed to $11.2M from $16.4M y/y, with SG&A down 3.5% y/y to $26.9M, but net loss widened to $17.0M from $15.5M due to $4.0M unfavorable change in conversion option derivative liabilities. Diluted EPS of $(0.15) aligns with 93.2M weighted shares. Cash fell to $30.3M from $49.7M y/y amid $15.2M operating outflow, partly offset by $15.4M private placement proceeds; long-term debt net dropped to $75.0M after $20.0M prepayment. The clinical trials segment was written off for $2.4M loss. Yet competition from larger oncology networks pressures margins.
8-K
TOI eyes PIPE amid growth
The Oncology Institute released an investor presentation on May 19, 2025, outlining a potential PIPE financing amid robust growth in its value-based oncology care model. The company projects 2025 revenue of $470 million, up from $393 million in 2024, fueled by $48 million in annualized net revenue from new capitation contracts across California, Nevada, Florida, and Oregon, while enhancing clinical productivity and dispensary attachments. Yet Adjusted EBITDA loss narrows to $(23.5) million. New contracts deliver ~2,000 bps MLR reductions for payors in year one.
8-K
TOI Q1 revenue up 10%
The Oncology Institute reported Q1 2025 revenue of $104.4 million, up 10.3% year-over-year, with gross profit surging 44.1% to $17.2 million amid pharmacy segment growth exceeding 20% and new capitated contracts adding over 100,000 lives. Adjusted EBITDA improved to $(5.1) million from $(10.9) million, bolstered by a $16.5 million private placement and note exchange enhancing liquidity. Yet net loss held at $19.6 million, pressured by non-cash charges. Momentum builds toward 2025 profitability.
IPO
Employees
Sector
Industry
AONC
American Oncology Network, Inc.
9.00-0.15
ASTH
Astrana Health Inc.
33.25-0.64
BZYR
Burzynski Research Institute, I
0.04-0.00
CCM
Concord Medical Services Holdin
5.30+0.06
CSBR
Champions Oncology, Inc.
6.76-0.04
CTOR
Citius Oncology, Inc.
1.75+0.01
HWAIF
HealWELL AI Inc.
1.04-0.02
MAIA
MAIA Biotechnology, Inc.
1.30-0.10
NEO
NeoGenomics, Inc.
10.28+0.36
OPCH
Option Care Health, Inc.
28.67+0.47